Senior Analyst
Nurix Therapeutics
Senior Analyst
Nurix Therapeutics
Drug discovery targeting ubiquitin E3 ligases
Senior Analyst, FP&A
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
In this role you will own FP&A and finance business-partner support for Nurix's Research and G&A functions, including budgeting, forecasting, reporting, variance analysis, and accounting close support. It is a high-ownership individual-contributor role for someone who wants to take full responsibility for their areas while partnering closely across the organization.
Nurix is a late-stage clinical organization developing targeted protein degradation medicines across a wholly owned and partnered pipeline, so the right candidate is comfortable in a fast-paced, evolving environment and eager to take on new scope as the business grows. Strong attention to detail, cross-functional partnering, problem-solving, and time management are essential. Must be proactive, deadline-oriented, and a self-starter.
Fit with Nurix Culture and Values
Salary: $130,000 - $158,900
Location: Brisbane, CA - Onsite
Drug discovery targeting ubiquitin E3 ligases
Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.
Explore more opportunities at Nurix Therapeutics